

Abstract of the Disclosure

5       The subject invention provides pharmaceutical compounds useful in the  
treatment of Type II diabetes. These compounds are advantageous because they are  
readily metabolized by the metabolic drug detoxification systems. Particularly,  
thiazolidinedione analogs that have been designed to include esters within the  
structure of the compounds are provided. This invention is also drawn to methods of  
treating disorders, such as diabetes, comprising the administration of therapeutically  
10       effective compositions comprising compounds that have been designed to be  
metabolized by serum or intracellular hydrolases and esterases. Pharmaceutical  
compositions of the ester-containing thiazolidinedione analogs are also taught.